2-(4-Hydroxy-2-methylphenyl)guanidine | 247234-45-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 2-(4-Hydroxy-2-methylphenyl)guanidine
• CAS: 247234-45-3
• 化学式: C₈H₁₁N₃O
• 分子量: 165.195
• InChiKey: NDZYLCSQPAHZCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  84.6
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-Hydroxy-2-methylphenyl)guanidine 、 4-<(dimethylamino)methylidene>-1,3,4,5-tetrahydro-2H-1-benzazepine-2,5-dione 在 sodium hydroxide 作用下， 以 异丙醇 为溶剂， 反应 0.5h， 以56%的产率得到2-(4-hydroxy-2-methylanilino)-5,7-dihydro-6H-pyrimido[5,4-d]-[1]benzazepin-6-one
  参考文献：
  名称：

  Identification of 2-Anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as Dual PLK1/VEGF-R2 Kinase Inhibitor Chemotypes by Structure-Based Lead Generation

  摘要：

  To develop multikinase inhibitors with dual PLK1/VEGF-R2 inhibitory activity, the d-annulated 1-benzazepin-2-one scaffold present in the paullone family of kinase inhibitors was investigated as a general structure template suitable for anchoring annulated heterocycles at the hinge region of the ATP binding site. For this purpose, the indole substructure of the paullones was replaced by other nitrogen containing heteroaromatics. The designed scaffolds were synthesized and tested on the indicated kinases. The 2-anilino-5.7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones were found to be VEGF-R2 inhibitors with selectivity against the insulin receptor kinase. The attachment of a methoxy group to the 9-position of the scaffold led to additional PLK1 inhibitory activity, which was explained by an alternative binding mode of the 9-methoxy derivatives. Selected members of the compound class inhibited the VEGF-R2 autophosphorylation in human umbilical vein endothelial cells, the sprouting of human umbilical vein endothelial cell speroids, and the proliferation of diverse cancer cell lines.

  DOI：

  10.1021/jm901388c

文献信息

• Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass
  申请人：Terkeltaub Robert

  公开号：US20070021496A1

  公开（公告）日：2007-01-25

  The present invention relates to improved diagnostic methods for early detection of a risk for developing an arthritic disorder in humans, and screening assays for therapeutic agents useful in the treatment of arthritic disorders, by comparing the levels of one or more indicators of altered mitochondrial function. Indicators of altered mitochondrial function include enzymes such as mitochondrial enzymes and ATP biosynthesis factors. Other indicators of altered mitochondrial function include mitochondrial mass, mitochondrial number and mitochondrial DNA content, cellular responses to elevated intracellular calcium and to apoptogens, and free radical production. Methods of treating, and of stratifying, human patients as such methods relate to disclosed indicators of altered mitchondrial function are also provided.

  本发明涉及改进的诊断方法，用于早期检测人类发展关节炎性疾病风险，并通过比较改变的线粒体功能指标的水平，筛选用于治疗关节炎性疾病的治疗剂的检测方法。改变的线粒体功能指标包括线粒体酶和ATP合成因子等酶。其他改变的线粒体功能指标包括线粒体质量、线粒体数量、线粒体DNA含量、细胞对细胞内钙离子和凋亡原的反应，以及自由基产生。还提供了与披露的改变的线粒体功能指标相关的治疗和分层人类患者的方法。
• Identification of 2-Anilino-9-methoxy-5,7-dihydro-6<i>H</i>-pyrimido[5,4-<i>d</i>][1]benzazepin-6-ones as Dual PLK1/VEGF-R2 Kinase Inhibitor Chemotypes by Structure-Based Lead Generation
  作者：Anne-Marie Egert-Schmidt、Jan Dreher、Ute Dunkel、Simone Kohfeld、Lutz Preu、Holger Weber、Jan E. Ehlert、Bettina Mutschler、Frank Totzke、Christoph Schächtele、Michael H. G. Kubbutat、Knut Baumann、Conrad Kunick

  DOI：10.1021/jm901388c

  日期：2010.3.25

  To develop multikinase inhibitors with dual PLK1/VEGF-R2 inhibitory activity, the d-annulated 1-benzazepin-2-one scaffold present in the paullone family of kinase inhibitors was investigated as a general structure template suitable for anchoring annulated heterocycles at the hinge region of the ATP binding site. For this purpose, the indole substructure of the paullones was replaced by other nitrogen containing heteroaromatics. The designed scaffolds were synthesized and tested on the indicated kinases. The 2-anilino-5.7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones were found to be VEGF-R2 inhibitors with selectivity against the insulin receptor kinase. The attachment of a methoxy group to the 9-position of the scaffold led to additional PLK1 inhibitory activity, which was explained by an alternative binding mode of the 9-methoxy derivatives. Selected members of the compound class inhibited the VEGF-R2 autophosphorylation in human umbilical vein endothelial cells, the sprouting of human umbilical vein endothelial cell speroids, and the proliferation of diverse cancer cell lines.